Fondaparinux versus enoxaparin for the prevention of venous thromboembolism: a comparative clinical and cost-effectiveness review
Pohar R, Argaez C
Record ID 32011001307
English
Authors' recommendations:
From two systematic reviews of RCTs that compared fondaparinux to enoxaparin, fondaparinux appeared to be more effective that enoxaparin in preventing VTE events in patients undergoing major orthopedic surgeries. As well, based on one systematic review, fondaparinux was more effective than enoxaparin in preventing VTE events in patients undergoing either hip fracture repair or major knee surgery. At the same time, cost-effectiveness analyses comparing the two drugs in preventing VTE in major orthopedic surgeries appeared to favour fondaparinux over enoxaparin, particularly in hip fracture surgery. However, the generalizability of the majority of studies to the Canadian health care system is uncertain given that the costs and consequences of the two drugs were not based upon Canadian data.
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/htis/L0051%20%20Fondaparinux%20vs.%20Enoxaparin%20for%20Thromboembolism%20final.pdf
Year Published:
2008
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Anticoagulants
- Cost-Benefit Analysis
- Polysaccharides
- Venous Thromboembolism
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.